Quick Answer
Jasper Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $28.69 million for the year ending 2025.
- Jasper Therapeutics, Inc. showed a decrease of -59.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Jasper Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2019: $1.21 million | Q1 2020: $1.06 million | Q2 2020: $914.2 thousand | Q3 2020: $757.5 thousand | Q1 2021: $590.6 thousand | Q2 2021: $309.7 thousand | Q3 2021: $100.91 million | Q1 2022: $70.40 million | Q2 2022: $60.81 million | Q3 2022: $50.95 million | Q1 2023: $129.40 million | Q2 2023: $115.81 million | Q3 2023: $103.87 million | Q1 2024: $118.48 million | Q2 2024: $106.82 million | Q3 2024: $92.50 million | Q1 2025: $48.80 million | Q2 2025: $39.51 million | Q3 2025: $50.90 million.
- Over the full 7 years of available data (2019 to 2025), Jasper Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 2,265.9%.
- Historical annual values: Fiscal year 2025: $28.69 million | Fiscal year 2024: $71.64 million | Fiscal year 2023: $86.89 million | Fiscal year 2022: $38.25 million | Fiscal year 2021: $84.70 million | Fiscal year 2020: $19.84 million | Fiscal year 2019: $1.21 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: